<PAGE>
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A1
(MARK ONE)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1995
OR
[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NUMBER 1-10392
U.S. BIOSCIENCE, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 23-2460100
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
ONE TOWER BRIDGE
100 FRONT STREET
WEST CONSHOHOCKEN, PA 19428
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (610) 832-0570
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
NAME OF EACH EXCHANGE ON
TITLE OF EACH CLASS WHICH REGISTERED
------------------- ------------------------
Common Stock ($.005 par value) American Stock Exchange
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:
None
(TITLE OF CLASS)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes. X No.___
---
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to
the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]
As of March 4, 1996, the aggregate market value of the voting stock held by
non-affiliates of the registrant was $293,983,000.*
As of March 4, 1996, the number of outstanding shares of the registrant's
Common Stock was 43,378,620.
DOCUMENTS INCORPORATED BY REFERENCE
Part III--Portions of the registrant's definitive Proxy Statement with respect
to the registrant's 1996 Annual Meeting of Stockholders, to be filed
not later than 120 days after the close of the Registrant's fiscal
year.
__________
* Calculated by excluding all shares held by executive officers, directors and
five percent shareholders of the registrant without conceding that all such
persons are "affiliates" of the registrant for purposes of the federal
securities laws.
================================================================================
<PAGE>
ITEM 14. EXHIBITS
This amendment to the Registrant's Form 10-K for the fiscal year
ended December 31, 1995 (the "1995 Form 10-K") amends and modifies the 1995
Form 10-K only to reflect the filing of Exhibit 27 to the 1995 Form 10-K.
<PAGE>
SIGNATURES
Pursuant to the requirement of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
U.S. BIOSCIENCE, INC.
Date: April 30, 1996 By: /s/ PHILIP S. SCHEIN
------------------------
PHILIP S. SCHEIN, M.D.
Chief Executive Officer and Chairman
<PAGE>
EXHIBIT INDEX
Exhibit
No. Description
- ------- -----------
27 Financial Data Schedule pursuant to
Article 5 of Regulation S-X.
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-END> DEC-31-1995
<CASH> 41,618,800
<SECURITIES> 3,977,400
<RECEIVABLES> 945,100
<ALLOWANCES> 142,600
<INVENTORY> 2,165,100
<CURRENT-ASSETS> 55,546,000
<PP&E> 10,280,000
<DEPRECIATION> 3,945,700
<TOTAL-ASSETS> 61,880,300
<CURRENT-LIABILITIES> 12,969,000
<BONDS> 20,123,400
0
0
<COMMON> 210,500
<OTHER-SE> 28,577,400
<TOTAL-LIABILITY-AND-EQUITY> 61,880,300
<SALES> 8,724,000
<TOTAL-REVENUES> 31,345,100
<CGS> 2,558,500
<TOTAL-COSTS> 31,327,900
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 255,000
<INCOME-PRETAX> (237,800)
<INCOME-TAX> 0
<INCOME-CONTINUING> (237,800)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (237,800)
<EPS-PRIMARY> (0.01)
<EPS-DILUTED> (0.01)
</TABLE>
